Epinephrine is the first-line treatment for severe allergic reactions, but far too often, people do not use or get it when needed. The FDA’s recent approval of neffy®, an epinephrine nasal spray , is a huge breakthrough. The allergy community now has a treatment option for severe and potentially life-threatening allergic reactions that does not use a needle. “An epinephrine nasal spray like neffy offers a new treatment option for people with anaphylaxis,“ said Kenneth Mendez, President and…
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik: Asthma and Allergy Foundation of America (AAFA)
Kommentare und Fragen
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Quick-Links
Aktuelles von Asthma and Allergy Foundation of America
- Wildfire Relief Efforts for Los Angeles Region
- AAFA Releases 2025 State Honor Roll™ Report
- Wildfires and How They Affect Air Quality and Asthma
- What You Need to Know About the $35 Price Cap on Asthma Inhalers
- AAFA’s Major Achievements in 2024
- Understanding Mild to Moderate Asthma (Video)
- December Research Update: Impact of Changing Inhaler Market on Asthma, Air Pollution, and Solar Urticaria
- Gifts to Give People with Asthma and Allergies
- How Can You Tell the Difference Between COVID-19, a Cold, the Flu, RSV, Allergies, and Asthma?
- Coronavirus (COVID-19): What People With Asthma Need to Know
